Drug Trial Radar · NCT03869632
First in Human Dose Escalation Study of YL-13027 in Subjects With Advanced Stage Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 16, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
36
Planned (sponsor's estimate)
Start
Mar 19, 2019
Primary completion
Apr 30, 2021
Study completion Jun 30, 2022
Sponsor
- Lead sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 11, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
YL-13027-001 is a phase I open-label, first in human, dose escalation study which investigate the tolerability, safety, pharmacokinetics (PK) and efficacy of YL-13027 in subjects with advanced stage solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
YL-13027Drug
Daily doses by oral administration on each day of each 28 day cycle. Starting dose is 60mg, with escalation to 360mg, and subsequent dose escalation using a modified Fibonacci algorithm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limited toxicities evaluated with NCI-CTC AE v5.0Time frame: within 28 days after the first dose
- Adverse events evaluated by NCI CTCAE v5.0Time frame: from the first dose to within 30 days after the last dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai East Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.